Notice of Preliminary Results and Investor Presentation

LONDON AND PHILADELPHIA - May 13, 2026 -  Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION^®, a tumor-activated oncology delivery platform, confirms it will announce its unaudited preliminary results for the year ended December 31, 2025 ("FY25"), on May 19, 2026.

Christina Coughlin, Chief Executive Officer, and Brian Hahn, Chief Financial Officer, will deliver a live presentation via Investor Meet Company at 14:00 BST on May 19, 2026.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 BST on May 18, 2026, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via:  https://www.investormeetcompany.com/avacta-group-plc/register-investor

Investors who already follow Avacta on the Investor Meet Company platform will automatically be invited.

The Company will also post the results presentation on its website at the following page: https://avacta.com/investors/investor-resources/.

-Ends-

For further information from Avacta, please contact:

About Avacta - https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies. 

Our pre|CISION® PDCs leverage this tumor-specific release mechanism to provide unique benefits over traditional antibody drug conjugates, releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled pre|CISION® version of doxorubicin that delivers the payload directly in the tumor with limited peripheral blood exposure and has demonstrated preliminary activity in tumor types sensitive to doxorubicin including salivary gland cancer and soft tissue sarcoma. 

About AVA6103 (FAP-Exd)

AVA6103 is the second clinical candidate and is based on the innovative pre|CISION^® sustained release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure.  AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload.